Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial

Authors:

Abstract
No abstract available
Funding Information
  • U.S. Department of Health and Human Services
  • Biomedical Advanced Research and Development Authority (75A50120C00001)

This publication has 17 references indexed in Scilit: